Prior to the ICER meeting to review evidence and vote on cost-effectiveness ratings for NSCLC treatments, five prominent oncologists...

I have extensive experience in “real world” policy-setting and decision-making and I am puzzled about the motivations regarding the...

A McGivney Global Advisors op-ed on Oncology Value Metrics and ICER was referenced by the Biotechnology Industry Organization, quoting...